Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

2021730 citationsJournal Articlehybrid Open Access

Authors

Ángela Lamarca · The Christie NHS Foundation Trust

Daniel H. Palmer · University of Liverpool

Harpreet Wasan · Hammersmith Hospital

Paul J. Ross · Guy's and St Thomas' NHS Foundation Trust

Yuk Ting · University of Birmingham

Arvind Arora · Nottingham University Hospitals NHS Trust

Stephen Falk

Abstract

Cancer Research UK, StandUpToCancer, AMMF (The UK Cholangiocarcinoma Charity), and The Christie Charity, with additional funding from The Cholangiocarcinoma Foundation and the Conquer Cancer Foundation Young Investigator Award for translational research.

Topics & Keywords

Cholangiocarcinoma and Gallbladder Cancer Studies Gallbladder and Bile Duct Disorders Pediatric Hepatobiliary Diseases and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Lancet Oncology

Volume 22, Issue 5, pp. 690-701

DOI: 10.1016/s1470-2045(21)00027-9

Field-Weighted Citation Impact: 115.38